AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
ALTEPLASE
6 registrations across 4 African markets— 3 active
Markets with ALTEPLASE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Actilyse, powder and solvent for solution for… Powder And Solvent For Solution For Injection | 🇰🇪Kenya | Boehringer Ingelheim international GmbH | active | Mar 2031 |
| Actilyse Powder** Powder for injection | 🇳🇬Nigeria | Fensyl MHP Consulting Limited | active | Dec 2025 |
| ACTILYSE Pdre p.prep.injectable / 20 mg | 🇹🇳Tunisia | BOEHRINGER INGELHEIM FRANCE | expired | Jan 2003 |
| ACTILYSE Pdre p.prep.injectable / 10 mg | 🇹🇳Tunisia | BOEHRINGER INGELHEIM FRANCE | expired | Jan 2003 |
| ACTILYSE Pdre p.prep.injectable / 50 mg | 🇹🇳Tunisia | BOEHRINGER INGELHEIM FRANCE | expired | Jan 2003 |
| ACTILYSE 50 mg | 🇿🇦South Africa | Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale | active | Jan 1900 |
ALTEPLASE in Africa — Regulatory Overview
ALTEPLASE is registered across 4 African markets with 6 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tunisia, Kenya, Nigeria, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 6 registrations, 3 (50%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.